Novartis Czech Republic made a net profit of CZK 71.0 mil with revenues of CZK 6,312 mil in 2017, down by 6.08% and down by 1.25%, respectively, compared to the previous year. This translates into a net margin of 1.12%.
On the operating level, EBITDA reached CZK 138 mil, down 18.9% compared to the previous year. Over the last five years, the company's EBITDA has risen 14.6% a year on average.
The company generated cash, defined by a sum of net profit and depreciation, of CZK 98.1 mil or 1.55% of sales. When investments are excluded, free cash flow reached CZK -33.2 mil, or -0.526% of sales in 2017.
In the last five years, the company generated free cash flow of CZK 178 mil. That compares to a cumulative net profit of CZK 364 mil in the same period.
You can see all the company’s data at Novartis Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
